Search results for "METASTASES"

showing 10 items of 117 documents

The Expression and Prognostic Significance of VEGF and CXCR4 in Gastric Cancer: Correlation with Angiogenesis, Lymphangiogenesis and Progression

2022

The cellular response to hypoxia includes the expression of hypoxia-inducible factor-1 (HIF-1) and its target genes: vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4). The aim of this study was to investigate the expression and prognostic significance of VEGF and CXCR4, which are responsible for angiogenesis and progression in gastric cancer. Twenty-eight gastric cancer patients were analyzed. The mRNA expression was examined in primary tumors and corresponding normal gastric mucosa by RT-PCR. The protein level was examined by immunohistochemistry staining. The high expression of VEGF and CXCR4 was found in 71.0 and 64.0% of tumors, respectively. The mean levels…

Microbiology (medical)gastric cancer; VEGF; CXCR4; angiogenesis; lymphangiogenesis; lymph node metastasesGeneral MedicineMolecular BiologyMicrobiologyCurrent Issues in Molecular Biology
researchProduct

Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer.

2011

Abstract Purpose. Tyrosine 1248 is one of the autophosphorylation sites of human epidermal growth factor receptor (HER)-2. We determined the prognostic value of the expression level of tyrosine 1248–phosphorylated HER-2 (pHER-2) in patients with HER-2+ primary breast cancer using a reverse-phase protein array. Patients and Methods. The optimal cutoff value of pHER-2 for segregating disease-free survival (DFS) was determined by receiver operating characteristic (ROC) curve analysis. Five-year DFS for pHER-2 expression level was estimated with the Kaplan-Meier method using both derivation (n = 162) and validation (n = 227) cohorts. Results. Of the 162 patients in the derivation cohort, 26 had…

OncologyAdultCancer Researchmedicine.medical_specialtyPathologyReceptor ErbB-2Breast NeoplasmsMetastasesDisease-Free SurvivalBreast cancerBreast cancerReverse-phase protein arrayInternal medicineBreast CancermedicineHumansTyrosinePhosphorylationIn Situ Hybridization FluorescenceAgedAged 80 and overReceiver operating characteristicintegumentary systembusiness.industryAutophosphorylationReverse phase protein lysate microarrayMiddle Agedmedicine.diseasePrognosisImmunohistochemistryOncologyHER-2PhosphorylationImmunohistochemistryFemalePrimary breast cancerbusinessThe oncologist
researchProduct

Sentinel node biopsy for malignant melanoma: a staging procedure only?

2010

Sentinel node biopsy (SNB) is an established staging tool for malignant melanoma. It allows identification of patients with metastatic disease at a very early stage and to collect accurate and complete prognostic information for these patients. Having noted that in a relevant percentage of patients the sentinel node is the only site of metastases, some authors have postulated a therapeutic role for SNB. In this paper, the possibility of a therapeutic role of SNB is evaluated. Relevant literature on the topic has been analyzed. Several findings suggest that not all patients with a positive SNB have further lymph node involvement. The prognostic indicators currently available do not significa…

OncologyBiologic markermedicine.medical_specialtymedicine.diagnostic_testbusiness.industryMelanomaSettore MED/19 - Chirurgia PlasticaDiseaseSentinel nodemedicine.diseasemedicine.anatomical_structureSentinel lymph node biopsy melanoma . Melanoma lymph node metastases . Melanoma prognosis . Prognostic false positivity . Melanoma lymphadenectomyInternal medicineStaging procedureBiopsymedicineSurgeryStage (cooking)businessLymph nodeEuropean Journal of Plastic Surgery
researchProduct

Comparative Analyses of Two Established Scores to Assess the Stability of Spinal Bone Metastases Before and After Palliative Radiotherapy

2021

Background and PurposeTo compare two validated spinal instability scores regarding the stabilizing effects and skeletal-related events (SREs) of palliative radiotherapy (RT) in patients with spinal bone metastases (SBM).Materials and MethodsTwo hundred eighty-two osteolytic SBM of lung or breast cancer patients were analyzed for stability before and following RT based on the Spinal Instability Neoplastic Score (SINS) or the Taneichi score. Score concordance was quantified by absolute agreement and Cohen’s kappa coefficient. SREs were defined as fractures or local progression after RT. OS was quantified as the time between the start of RT and death from any cause.ResultsAt 3 and 6 months aft…

OncologyCancer Researchmedicine.medical_specialtyFuture studiesConcordancemedicine.medical_treatmentCohen's kappaBreast cancerPalliative radiotherapyInternal medicinemedicineSINSRC254-282radiotherapyOriginal Researchbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensSpinal instabilityspinal bone metastasesmedicine.diseaseskeletal-related eventsRadiation therapyinstabilityOncologybusinessKappaFrontiers in Oncology
researchProduct

Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth f…

2014

Sir,We have read with great interest the article in press ofAurilio et al., A meta-analysis of oestrogen receptor, pro-gesterone receptor and human epidermal growth factorreceptor 2 discordance between primary breast cancerand metastases (http://dx.doi.org/10.1016/j.ejca.2003.10.004), which will appear in Eur J Cancer. In the paper,the Authors have performed a meta-analysis of the stud-ies published in the literature concerning the discor-dance rate in oestrogen receptor (ER), progesteronereceptor (PgR) and HER2 status between primarytumour and corresponding relapse. It is well known thata considerable controversy concerns the issue of hor-mone receptors (HRs) expression as well as HER2 sta…

OncologyCancer Researchmedicine.medical_specialtyPathologyLetter to the editorBreast NeoplasmsSettore MED/08 - Anatomia PatologicaErbB-2breast cancer metastases oestrogen receptor human epidermal growth factor receptor 2Internal medicineProgesterone receptorReceptorsmedicineHumansOestrogen receptorskin and connective tissue diseasesReceptorProgesteronebusiness.industryCancermedicine.diseaseEstrogenRegimenOncologyLOCALLY RECURRENT HORMONE-RECEPTOR HER2 STATUS IMPACTMeta-analysisBreast Neoplasms; Female; Humans; Receptor ErbB-2; Receptors Estrogen; Receptors ProgesteroneImmunohistochemistryFemalebusinessReceptor
researchProduct

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SR…

OncologyMaleAnatomy and PhysiologyBone diseaseEpidemiologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentMetastasisMetastasisbone metastasesRenal cell carcinomaBasic Cancer ResearchMedicineMusculoskeletal SystemMultidisciplinaryDiphosphonatesrenal cell carcinoma bone metastasis zoledronic acidQRBone metastasisKidney NeoplasmsOncologyItalyObservational StudiesDisease ProgressionMedicineFemaleCancer Epidemiologymedicine.drugResearch Articlemedicine.medical_specialtyClinical Research DesignSciencerenal cancerBone NeoplasmsInternal medicineHumansBonerenal cancer; bone metastasesRetrospective Studiesbusiness.industryRenal Cell CarcinomaCancerCancers and NeoplasmsBone fracturemedicine.diseaseSurgeryRadiation therapyGenitourinary Tract TumorsZoledronic acidbusiness
researchProduct

Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.

2010

<i>Objectives:</i> FOLFOX-4 and FOLFIRI are considered equivalent in terms of activity and efficacy as first-line chemotherapy in metastatic colorectal cancer (mCRC). The monoclonal antibody (mAb) cetuximab showed intrinsic activity as a single agent in mCRC and was approved in combination with CPT-11 for patients who failed previous CPT-11-based treatment. The purpose of this phase II study was to evaluate the activity and safety of FOLFOX-4 plus cetuximab in untreated mCRC patients. <i>Methods:</i> Untreated patients with measurable metastatic disease and expressing epidermal growth factor receptor (EGFR) received cetuximab at a loading dose of 400 mg/m<sup>2…

OncologyMaleCancer ResearchLung NeoplasmsOrganoplatinum CompoundsSettore MED/06 - Oncologia MedicaColorectal cancerMetastaseLeucovorinPhases of clinical researchCetuximabColorectal Neoplasmmedicine.disease_causeMetastasisFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene ProteinFOLFOX-4CetuximabLiver NeoplasmsAntibodies MonoclonalGeneral MedicineMiddle AgedErbB ReceptorsColorectal carcinomaOncologyLiver NeoplasmFOLFIRIFemaleKRASFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyAntibodies Monoclonal HumanizedBRAFProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsKRASmedicineHumansAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundCancerras Proteinmedicine.diseasedigestive system diseasesSurgeryLung NeoplasmMutationras ProteinsReceptor Epidermal Growth FactorbusinessBRAF; Cetuximab; Colorectal carcinoma; FOLFOX-4; KRAS; Metastases; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor Epidermal Growth Factor; ras Proteins; Oncology; Cancer ResearchOncology
researchProduct

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-…

2016

Objectives: To investigate cancer-specific mortality and other-cause mortality in prostate cancer patients with nodal metastases. Methods: The study included 411 patients treated with radical prostatectomy and pelvic lymph node dissection for prostate cancer with lymph node metastases at 10 tertiary care centers between 1995 and 2014. Kaplan–Meier analyses were used to assess cancer-specific mortality-free survival rates at 8 years' follow up in the overall population, and after stratifying patients according to clinical and pathological parameters. Uni- and multivariable competing risk Cox regression analyses were used to assess cancer-specific mortality and other-cause mortality. Finally,…

OncologyMalemedicine.medical_treatment030232 urology & nephrologyProstate cancer0302 clinical medicineRobotic Surgical ProceduresLymph nodeeducation.field_of_studyProstatectomyMortality rateLymph NodePrognosiscancer-specific mortality competing risk analysis lymph node metastases other-cause mortality radical prostatectomylymph node metastaseDissectionmedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisLymphSurvival Analysicancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomycancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomy; Urologyother-cause mortalityHumanlymph node metastasesRiskmedicine.medical_specialtyRobotic Surgical ProcedurePrognosiUrologyPopulationUrologycancer-specific mortality03 medical and health sciencesInternal medicinemedicineHumanseducationcompeting risk analysiProstatectomybusiness.industryProportional hazards modelcompeting risk analysisProstatic NeoplasmsLymphatic MetastasiProstate-Specific Antigenmedicine.diseaseSurvival Analysisradical prostatectomyProstatic NeoplasmLymph Node ExcisionLaparoscopyLymph Nodesbusiness
researchProduct

Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodie…

2021

Background: Metastatic colorectal cancer (mCRC) with wild type expression of RAS and RAF genes can be treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, such as cetuximab, in combination with chemotherapy. Skin toxicity represents the most serious and frequent side effect in these patients. Skin manifestations occur in approximately 80% of patients. In this study, we investigated the consequences on body image and quality of life (QoL) of patients with severe skin toxicity. Methods: One hundred patients were enrolled with mCRC. All patients signed informed consent and completed questionnaires to assess QoL and body discomfort. Toxicity was assessed on Common Te…

OncologyQuality of lifeCancer Researchmedicine.medical_specialtySide effectColorectal cancermedicine.medical_treatmentPsychological reactionsCetuximabMetastasesQuality of lifeInternal medicinemedicineChemotherapyChemotherapySkin rashCetuximabintegumentary systembusiness.industryMetastatic colorectal carcinomaCommon Terminology Criteria for Adverse Eventsmedicine.diseaseRashhumanitiesOncologyToxicityOriginal Articlemedicine.symptombusinessmedicine.drugWorld journal of oncology
researchProduct

New molecular targets in bone metastases.

2010

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as " vicious circle," a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results fr…

Oncologymedicine.hormonemedicine.medical_specialtyPathologyCathepsin KProto-Oncogene Proteins pp60(c-src)Antineoplastic AgentsBone NeoplasmsBone NeoplasmAntibodies Monoclonal HumanizedEndothelinMetastasisAntineoplastic AgentEndothelinsBone metastases; Molecular targets; Animals; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bone Neoplasms; Cathepsin K; Denosumab; Endothelins; Humans; Proto-Oncogene Proteins pp60(c-src); RANK Ligand; Medicine (all); Oncology; Radiology Nuclear Medicine and ImagingInternal medicineMedicineAnimalsHumansRadiology Nuclear Medicine and imagingMolecular targetbiologyAnimalbusiness.industryMedicine (all)EndothelinsRANK LigandCancerBone metastasisAntibodies MonoclonalGeneral Medicinemedicine.diseaseClinical trialBone metastaseDenosumabOncologyRANKLCancer cellbiology.proteinDenosumabbusinessHumanmedicine.drugCancer treatment reviews
researchProduct